EGFR and neoplasm: In lung cancer, elevated GBP1 is linked to erlotinib resistance, serving as a prognostic warning for EGFR-targeted therapies and detectable via quantitative PCR (qPCR), proteomic assays, or circulating tumor DNA analysis [68].